Limited Thyroidectomy Achieves Equivalent Survival to Total Thyroidectomy for Early Localized Medullary Thyroid Cancer Authors: Jessan A Jishu, Mohammad H Hussein, Salman Sadakkadulla, Solomon Baah, Yaser Y Bashumeel, Eman Toraih, Emad Kandil, Maurizio Iacobone, Francesca Torresan Published: 2024 ABSTRACT Simple SummaryMedullary thyroid cancer is a rare but severe variant of thyroid cancer. The mainstay treatment for this condition is surgery to remove the entire thyroid gland, or total thyroidectomy. However, recent studies have found that a less extensive thyroidectomy may optimize survival outcomes for early localized tumors. We compared the survival and mortality outcomes between patients with such tumors who underwent total thyroidectomy and lobectomy/subtotal thyroidectomy to understand which surgical approach can improve survival rates in early-stage medullary thyroid cancer.Keywords: MTC, medullary thyroid cancer, thyroidectomy, lobectomy, T1N0M0, T1N1M0, SEER, endocrine 1. Introduction Medullary thyroid cancer (MTC) is a neuroendocrine tumor originating from the parafollicular cells of the thyroid, accounting for approximately 5–10% of all thyroid cancers [1,2], and causing up to 14% of all thyroid disease-related deaths [3]. The hallmark of MTC is the secretion of calcitonin, which serves as a sensitive tumor marker for diagnosis and monitoring [4]. MTC can occur sporadically or be inherited in an autosomal dominant pattern as part of multiple endocrine neoplasia type 2 (MEN2) syndromes [2]. The hereditary forms are caused by activating mutations in the rearranged during transfection (RET) proto-oncogene [5]. Compared to well-differentiated thyroid cancers, MTC is more clinically aggressive with a high propensity for lymph node and distant metastases [6]. Regional lymph node involvement is present in up to 75% of patients at diagnosis and 10–15% have distant metastases to sites like liver, lung, and bone [7]. Five-year survival rates can reach up to 91% but decline considerably with extrathyroidal extension or advanced stage [8,9]. Given its clinical aggressiveness, complete surgical resection is the only potentially curative option [10,11,12]. Total thyroidectomy with central compartment neck dissection has traditionally been the standard approach as it ensures the clearance of bilateral disease [13]. However, total thyroidectomy has risks including permanent hypoparathyroidism, recurrent laryngeal nerve injury, and thromboembolisms, with incidence rates being higher in patients of older age or with more comorbidities [14]. Given the potential complications, interest has grown in lesser procedures such as lobectomy/subtotal thyroidectomy for small early tumors [15]. Indeed, these surgeries are less extensive and thus remove less tissue and have lower risks. However, there are concerns about locoregional recurrence and mortality when compared to total thyroidectomy [11]. The 2015 American Thyroid Association guidelines recommend total thyroidectomy for most MTCs to ensure adequate disease clearance [3]. However, optimal surgical management for early localized lesions is less defined, representing a knowledge gap. Although total thyroidectomy is standard, lobectomy/subtotal thyroidectomy may allow comparable oncologic control for T1 tumors while avoiding surgical complications [16]. This study aims to address this clinical equipoise by utilizing a national cohort to compare survival outcomes between total thyroidectomy and lobectomy/subtotal thyroidectomy specifically for localized T1N0/1M0 MTC. 2. Materials and Methods 2.1. Data Source This retrospective cohort study utilized data from the Surveillance, Epidemiology, and End Results (SEER) program registry of the National Cancer Institute. SEER collects cancer incidence, treatment, and survival information from 17 population-based cancer registries, covering approximately 26.5% of the United States population (https://seer.cancer.gov/registries/data.html (accessed on 29 September 2023). 2.1.1. Study Population The study included patients who were diagnosed with pathologically confirmed MTC between 2000 and 2019. International Classification of Diseases for Oncology, 3rd edition (ICD-O-3) histology codes were used to identify MTC cases (codes 8345/3, 8346/3, 8347/3, 8510/3). Patients were included if they had histological T1 tumors with a maximum tumor dimension less than or equal to 2 cm. Patients were excluded if the MTC diagnosis was made only on autopsy or death certificate, had incomplete staging information, distant metastasis at diagnosis, prior or synchronous secondary malignancies, died within one month of diagnosis, or had unknown/missing data on survival. 2.1.2. Study Variables Baseline demographic (age, sex, race, ethnicity), socioeconomic (median household income, marital status, and geographical residency), tumor characteristics (year of diagnosis, histology, TNM stage, tumor size, extension, lymph node involvement, metastasis), and treatment details (type of surgery—total thyroidectomy, lobectomy/subtotal thyroidectomy, external beam radiation, systemic therapy) were extracted. Time to initiation of treatment dichotomized before and after 1 month from diagnosis was assessed. 2.1.3. Study Outcomes Patients undergoing total thyroidectomy were compared to those having lobectomy/subtotal thyroidectomy. The primary outcomes were overall mortality and thyroid cancer-specific mortality. Thyroid cancer-specific mortality was defined as death attributable to MTC documented in the SEER cause of death field. Overall mortality was defined as death from any cause. Secondary outcomes were recurrence and incidence of second primary malignancies. 2.1.4. Statistical Analysis Baseline characteristics were summarized using descriptive statistics. Thyroid cancer-specific mortality was estimated using Kaplan–Meier methods and differences between surgical groups (total thyroidectomy vs. lobectomy/subtotal thyroidectomy) were assessed using the log-rank test. Multivariable Cox proportional hazards regression was performed to determine the adjusted hazards ratio (HR) and 95% confidence interval (CI) for cancer-specific and overall mortality associated with type of surgery. Models were adjusted for potential confounders including age, sex, race, income, TNM stage, histology, systemic therapy, radiation, and treatment latency. Subgroup analysis by T and N stage was performed. The impact of various treatment approaches and latency time from diagnosis to treatment on survival were investigated. Two-sided p < 0.05 was considered statistically significant. All analyses were conducted using SPSS v28.0. 3. Results 3.1. Overall Cohorts 3.1.1. Characteristics of the Study Population A total of 398 patients with T1 MTC were identified, among whom 357 (89.7%) underwent surgery and 41 (10.3%) did not receive surgical treatment. The majority of patients were female (65.3%) and of White race (85.7%). The median age was 51 years (range 18–93 years), with 58.8% younger than 55 years. Pediatric patients accounted for 7.3% of the cohort (n = 29). The most common histological subtype was medullary carcinoma with amyloid stroma (52.5%), followed by medullary carcinoma without amyloid (41.2%). Over half had T1a tumors ≤1 cm (55.5%), while 44.5% were T1b >1–2 cm. Most were node-negative (N0, 70.4%), while 29.6% had nodal infiltration. Among the 398 patients, 357 (89.7%) received treatment while 41 (10.3%) did not undergo any intervention. Compared to the surgery group, those without surgery were older (mean age 61 vs. 50 years, p = 0.008), more likely male (53.7% vs. 32.5%, p = 0.009), urban residents (100% vs. 88.2%, p = 0.014), and presented with smaller T1a tumors (80.5% vs. 52.7%, p = 0.001) and less nodal involvement (N0 85.4% vs. 68.6%, p = 0.029). Details are presented in Table 1. Table 1Clinicopathological characteristics and disease outcomes of T1 MTC patients.CharacteristicsLevelsTotal Cohort (N = 398)Surgery (N = 357)No Surgery (N = 41)p-ValueDemographics Age (years)<55 years234 (58.8)218 (61.1)16 (39.0)0.008≥55 years164 (41.2)139 (38.9)25 (61.0)GenderFemale260 (65.3)241 (67.5)19 (46.3)0.009Male138 (34.7)116 (32.5)22 (53.7)RaceWhite341 (85.7)308 (86.3)33 (80.5)0.58Black23 (5.8)19 (5.3)4 (9.8)API31 (7.8)27 (7.6)4 (9.8)AI/AN3 (0.8)3 (0.8)0 (0.0)EthnicityNot Hispanic/Latino344 (86.4)311 (87.1)33 (80.5)0.23Hispanic/Latino54 (13.6)46 (12.9)8 (19.5)Marital statusMarried197 (60.1)14 (45.2)197 (60.1)0.52Domestic partner5 (1.5)0 (0.0)5 (1.5)Separated4 (1.2)1 (3.2)4 (1.2)Divorced19 (5.8)3 (9.7)19 (5.8)Widowed20 (6.1)2 (6.5)20 (6.1)Single83 (25.3)11 (35.5)83 (25.3)ResidencyUrban356 (89.4)315 (88.2)41 (100.0)0.014Rural 42 (10.6)42 (11.8)0 (0.0)Household annual incomeUSD 75,000+123 (34.5)19 (46.3)123 (34.5)0.60USD 70,000–74,99941 (11.5)2 (4.9)41 (11.5)USD 65,000–69,99943 (12.0)6 (14.6)43 (12.0)USD 60,000–64,99960 (16.8)5 (12.2)60 (16.8)USD 55,000–59,99924 (6.7)4 (9.8)24 (6.7)USD 50,000–54,99924 (6.7)1 (2.4)24 (6.7)USD 45,000–49,99921 (5.9)2 (4.9)21 (5.9)USD 40,000–44,9999 (2.5)2 (4.9)9 (2.5)USD 35,000–39,9996 (1.7)0 (0.0)6 (1.7) 0.05). Table 3Comparison between total thyroidectomy and less aggressive surgery.CharacteristicsLevelsLobectomy and Subtotal (N = 39)Total Thyroidectomy (N = 304)p-ValueDemographics Age (years)Pediatric1 (2.6)26 (8.6)0.34Adults38 (97.4)278 (91.4)<55 years22 (56.4)185 (60.9)0.61≥55 years17 (43.6)119 (39.1)GenderFemale29 (74.4)203 (66.8)0.37Male10 (25.6)101 (33.2)RaceWhite33 (84.6)261 (85.9)0.48Black1 (2.6)18 (5.9)API4 (10.3)23 (7.6)AI/AN1 (2.6)2 (0.7)EthnicityNot Hispanic/Latino37 (94.9)265 (87.2)0.19Hispanic/Latino2 (5.1)39 (12.8)Marital statusMarried24 (70.6)169 (59.3)0.15Domestic partner0 (0.0)5 (1.8)Separated0 (0.0)4 (1.4)Divorced3 (8.8)15 (5.3)Widowed4 (11.8)16 (5.6)Single3 (8.8)76 (26.7)MetropolitanMetropolitan >1 M pop19 (48.7)172 (56.6)0.18Metropolitan >250 K−1 M9 (23.1)81 (26.6)Metropolitan of <250 K2 (5.1)21 (6.9)Non-Metropolitan adj to Metropolitan5 (12.8)19 (6.3)Non-Metropolitan not adj to Metropolitan4 (10.3)11 (3.6)Household annual income 0.05). The data demonstrate that total thyroidectomy did not confer a survival advantage compared to lobectomy/subtotal thyroidectomy in T1 MTC patients with any demographic or tumor characteristic. Subgroup analysis comparing overall survival times in total thyroidectomy and lobectomy/subtotal thyroidectomy T1 MTC patients. The values of the mean in months and confidence intervals (CIs) are displayed on the plot for both lobectomy/subtotal thyroidectomy (blue) and total thyroidectomy (green) treatments. Log-rank test was used for comparisons. 3.2.6. Impact of Surgical Timing on Survival Beyond examining the extent of surgery, we also analyzed the impact of timing of initial treatment on survival outcomes in T1 MTC patients. Among the 357 patients who underwent surgery, 278 (77.9%) were treated within 1 month of diagnosis (early treatment), while 74 (20.7%) had delayed treatment exceeding 1 month. Patients with delayed treatment were more likely to be older (55.4% versus 35.6%, p = 0.003), present with nodal disease (41.9% versus 29.5%, p = 0.05), and receive systemic therapy (51.4% versus 26.3%, p < 0.001), as seen in Table 7. Older age (OR = 2.39, 95%CI = 1.40–4.07, p = 0.001) and nodal positivity (OR = 1.77, 95%CI = 0.99–3.13, p = 0.05) were independent risk factors for delayed treatment exceeding 1 month on multivariate analysis (Figure 5). Table 7Comparison between total thyroidectomy and less aggressive surgery.CharacteristicsLevelsEarly Treatment (N = 278)Late Treatment (N = 74)p-ValueDemographics Age (years)Pediatric28 (10.1)0 (0.0)0.001Adults250 (89.9)74 (100)<55 years179 (64.4)33 (44.6)0.003≥55 years99 (35.6)41 (55.4)GenderFemale183 (65.8)52 (70.3)0.49Male95 (34.2)22 (29.7)RaceWhite240 (86.3)66 (89.2)0.78Black15 (5.4)3 (4.1)API20 (7.2)5 (6.8)AI/AN3 (1.1)0 (0.0)EthnicityNot Hispanic/Latino245 (88.1)63 (85.1)0.55Hispanic/Latino33 (11.9)11 (14.9)Marital statusMarried158 (61.7)37 (54.4)0.64Domestic partner4 (1.6)1 (1.5)Separated3 (1.2)1 (1.5)Divorced13 (5.1)5 (7.4)Widowed13 (5.1)7 (10.3)Single65 (25.4)17 (25.0)MetropolitanMetropolitan >1 M pop153 (55.0)41 (55.4)0.99Metropolitan >250 K−1 M73 (26.3)20 (27.0)Metropolitan of <250 K19 (6.8)5 (6.8)Non-Metropolitan adj to Metropolitan20 (7.2)5 (6.8)Non-Metropolitan not adj to Metropolitan13 (4.7)3 (4.1)Household annual income